{"id":19980,"date":"2024-12-27T16:24:06","date_gmt":"2024-12-27T08:24:06","guid":{"rendered":"https:\/\/flcube.com\/?p=19980"},"modified":"2024-12-27T16:24:08","modified_gmt":"2024-12-27T08:24:08","slug":"ascentage-pharma-announces-secondary-offering-on-nasdaq-expanding-global-reach","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19980","title":{"rendered":"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach"},"content":{"rendered":"\n

China-based Ascentage Pharma (HKG: 6855<\/a>) has unveiled plans for a secondary offering of up to 33,739,347 shares on the Nasdaq, as reported by the China Securities Regulatory Commission. This strategic move is aimed at bolstering the company’s financial capacity to further its research and development efforts in innovative oncology treatments.<\/p>\n\n\n\n

Ascentage Pharma’s Global Biopharma Ambitions<\/strong>
Ascentage Pharma, a global biopharmaceutical company dedicated to the research and development of innovative drugs for the treatment of tumors, made its debut in Hong Kong in October 2019. The company has since been at the forefront of cancer therapy innovation, with a rich product pipeline targeting key proteins in the apoptosis pathway, including Bcl-2, IAP, and MDM2-p53.<\/p>\n\n\n\n

Ongoing Clinical Trials and Pipeline Expansion<\/strong>
Currently, Ascentage Pharma has over 40 clinical trials in progress across China, the US, Australia, and Europe. These trials are indicative of the company’s commitment to advancing novel therapies and improving patient outcomes in the field of oncology. The proceeds from the secondary offering on Nasdaq are expected to support the continued development of these promising drug candidates and potentially accelerate their path to market.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to…<\/p>\n","protected":false},"author":1,"featured_media":19981,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[200,30,985,72],"class_list":["post-19980","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ascentage-pharma","tag-biotech","tag-hkg-6855","tag-ipo"],"yoast_head":"\nAscentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to 33,739,347 shares on the Nasdaq, as reported by the China Securities Regulatory Commission. This strategic move is aimed at bolstering the company's financial capacity to further its research and development efforts in innovative oncology treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19980\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach\" \/>\n<meta property=\"og:description\" content=\"China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to 33,739,347 shares on the Nasdaq, as reported by the China Securities Regulatory Commission. This strategic move is aimed at bolstering the company's financial capacity to further its research and development efforts in innovative oncology treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19980\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-27T08:24:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-27T08:24:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122713.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"554\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19980#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19980\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach\",\"datePublished\":\"2024-12-27T08:24:06+00:00\",\"dateModified\":\"2024-12-27T08:24:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19980\"},\"wordCount\":198,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19980#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122713.png\",\"keywords\":[\"Ascentage Pharma\",\"Biotech\",\"HKG: 6855\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19980#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19980\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19980\",\"name\":\"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19980#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19980#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122713.png\",\"datePublished\":\"2024-12-27T08:24:06+00:00\",\"dateModified\":\"2024-12-27T08:24:08+00:00\",\"description\":\"China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to 33,739,347 shares on the Nasdaq, as reported by the China Securities Regulatory Commission. This strategic move is aimed at bolstering the company's financial capacity to further its research and development efforts in innovative oncology treatments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19980#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19980\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19980#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122713.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/122713.png\",\"width\":1080,\"height\":554,\"caption\":\"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19980#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach - Insight, China's Pharmaceutical Industry","description":"China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to 33,739,347 shares on the Nasdaq, as reported by the China Securities Regulatory Commission. This strategic move is aimed at bolstering the company's financial capacity to further its research and development efforts in innovative oncology treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19980","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach","og_description":"China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to 33,739,347 shares on the Nasdaq, as reported by the China Securities Regulatory Commission. This strategic move is aimed at bolstering the company's financial capacity to further its research and development efforts in innovative oncology treatments.","og_url":"https:\/\/flcube.com\/?p=19980","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-27T08:24:06+00:00","article_modified_time":"2024-12-27T08:24:08+00:00","og_image":[{"width":1080,"height":554,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122713.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19980#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19980"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach","datePublished":"2024-12-27T08:24:06+00:00","dateModified":"2024-12-27T08:24:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19980"},"wordCount":198,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=19980#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122713.png","keywords":["Ascentage Pharma","Biotech","HKG: 6855","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19980#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19980","url":"https:\/\/flcube.com\/?p=19980","name":"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=19980#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=19980#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122713.png","datePublished":"2024-12-27T08:24:06+00:00","dateModified":"2024-12-27T08:24:08+00:00","description":"China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to 33,739,347 shares on the Nasdaq, as reported by the China Securities Regulatory Commission. This strategic move is aimed at bolstering the company's financial capacity to further its research and development efforts in innovative oncology treatments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19980#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19980"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=19980#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122713.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122713.png","width":1080,"height":554,"caption":"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19980#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/122713.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19980"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19980\/revisions"}],"predecessor-version":[{"id":19982,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19980\/revisions\/19982"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/19981"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}